What it's for (Indications)
- Memantine, a low-to-moderate affinity uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is specifically indicated for the symptomatic treatment of moderate to severe Alzheimer's disease.
- Alzheimer's disease is a progressive neurodegenerative disorder characterized by a decline in cognitive functions, including memory, thinking, reasoning, and behavior, ultimately impairing the ability to perform activities of daily living.
- The rationale for memantine's use stems from the hypothesis that chronic overstimulation of NMDA receptors by pathologically elevated levels of glutamate in the brain contributes to excitotoxicity and neuronal damage, which are hallmarks of Alzheimer's pathophysiology.
- By selectively blocking tonic, but not phasic, activation of NMDA receptors, memantine modulates glutamatergic neurotransmission without interfering with physiological synaptic transmission essential for learning and memory.
- Its therapeutic aim is to improve cognitive function, slow the rate of decline in functional abilities, and manage some of the behavioral symptoms associated with moderate to severe stages of the disease.
- Memantine can be used as monotherapy or in conjunction with cholinesterase inhibitors, particularly when patients have progressed beyond mild stages or have not tolerated other treatment options.
- The treatment is not curative but seeks to provide symptomatic relief and improve the quality of life for both patients and their caregivers.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For memantine hydrochloride extended-release capsules: The recommended starting dose is 7 mg once daily. The dose should be increased in 7 mg increments with a minimum interval of one week between increases, to a recommended maintenance dose of 28 mg once daily. Dose increases should only occur if the previous dose was well tolerated. For patients with severe renal impairment, the recommended maintenance dose is 14 mg once daily. |
Safety & Warnings
Common Side Effects
- Commonly observed adverse reactions include headache, dizziness, and diarrhea.
- Other reported side effects are hallucinations, confusion, drowsiness, tiredness, hypertension, constipation, shortness of breath, balance disorders, and elevated liver function tests.
Serious Warnings
- Black Box Warning: Memantine does not carry a formal FDA Black Box Warning. However, healthcare professionals should be aware of several serious warnings and precautions that warrant careful consideration during its administration. Conditions that elevate urine pH, such as renal tubular acidosis or severe urinary tract infections caused by Proteus species, can significantly reduce the renal clearance of memantine, potentially leading to increased plasma concentrations and a heightened risk of adverse effects. Therefore, vigilant monitoring and possible dose adjustments are necessary in patients with these conditions. Additionally, neuropsychiatric adverse reactions, including hallucinations, confusion, agitation, and aggression, have been reported. These events necessitate careful clinical assessment, especially in patients with a history of psychiatric disorders, to determine the continued appropriateness of memantine therapy. While not a boxed warning, these critical safety considerations underscore the importance of individualized patient evaluation and continuous monitoring throughout the treatment course.
- Use with caution in patients with liver and kidney impairment (dose adjustment required for severe renal impairment).
- Precautions should be taken in patients with epilepsy, a history of convulsions, recent myocardial infarction, heart failure, or uncontrolled hypertension.
- Pregnancy: Can be used with caution as no evidence of human risk has been found.
- Lactation: Advised to observe cautiousness.
- Alcohol: Avoid consumption during treatment.
How it Works (Mechanism of Action)
Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) N-methyl-D-aspartate (NMDA) receptor antagonist, binding preferentially to NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease.